Similar Pharmacokinetics and Pharmacodynamics of Biosimilar SAR342434 Insulin Lispro and Japan‐Approved Humalog Insulin Lispro in Healthy Japanese Subjects

• Published in: Clinical pharmacology in drug development Vol. 11; no. 6; pp. 754 - 760
• Main Authors: Shiramoto, Masanari, Yoshihara, Tatsuya, Schmider, Wolfgang, Takahashi, Yoshinori, Nowotny, Irene, Kajiwara, Miyuki, Muto, Hideya
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01-06-2022; John Wiley and Sons Inc
• Subjects: Biological products; biosimilar; Glucose; healthy Japanese subjects; Insulin; insulin analog; insulin lispro; Original; Pharmacodynamics; Pharmacokinetics; SAR342434; Japan; healthy Japanese subjects; insulin analog; insulin lispro; SAR342434; biosimilar
• ISSN: 2160-763X; 2160-7648
• DOI: 10.1002/cpdd.1068

This phase 1 study compared the pharmacokinetic (PK) and glucose pharmacodynamic (PD) characteristics of biosimilar SAR342434 insulin lispro and Japan‐reference Humalog insulin lispro. This was a randomized, double‐blind, 2‐period, crossover study. Thirty‐six healthy Japanese male subjects underwent a 10‐hour euglycemic clamp following a single subcutaneous 0.3‐U/kg dose of SAR342434 or Humalog. Insulin lispro concentration and blood glucose were measured, and the glucose infusion rate (GIR) was adjusted to maintain the target blood glucose level. Primary PK end points were maximum plasma insulin lispro concentration and area under the plasma insulin concentration–time curve (AUC) from time 0 to the last quantifiable concentration. Primary PD end points were area under the GIR–time curve from time 0 to 10 hours and maximum GIR. PK exposure (maximum plasma concentration and AUC from time 0 to the last quantifiable concentration) and PD activity (GIR‐AUC from time 0 to 10 hours and maximum GIR) were similar between treatments. Geometric mean ratios were close to 1, and the corresponding 90% and 95%CIs (PK and PD activity, respectively) were within the 0.80 to 1.25 equivalence range. SAR342434 and Humalog were well tolerated. In healthy Japanese males, SAR342434 and Humalog showed similar PK exposure profiles and PD potency, in support of SAR342434 use as a biosimilar product.